-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In patients with inflammatory bowel disease (IBD) in old age, there is little data on the safety and effectiveness of the anti-tumor necrosis factor (TNF).
older people generally reject the use of biologics for their own and economic reasons, while researchers in clinical observation also found that older people also had a higher failure rate after using TNF.
therefore, the purpose of this study is to compare the failure rates and safety of TNF drugs in IBD patients in different age groups.
researchers identified ibD patients who first used anti-TNF drugs through a prospective cohort study.
the regression of competitive risk is used to study treatment failures, which are defined as discontinuation due to adverse events or lack of efficacy, and discontinuation due to mitigation is a competitive risk.
study: A total of 895 IBD patients were selected.
began using anti-TNF at age 40 with 546 people (61.0% ) , 268 people who started using anti-TNF at age 40-59 , and 82 people who started using anti-TNF at age 60 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
the treatment failure rate of two groups of elderly patients (-40 years old) was higher (risk rate: 1.46, SHR age 40-59: 1.21; p? the SHR of the
elderly was 1.52 due to AE discontinuation and 1.11 due to lack of effectiveness. The combined use of
thiopental reduces the rate of treatment failure (SHR 0.78, 95% confidence interval (CI) 0.62-0.98, p-0.031).
elderly patients who started anti-TNF therapy for the first time had a higher rate of treatment failure than younger patients, but using thionine at the baseline at the same time reduced the failure rate of the drug.
at the same time, senior patients with IBD showed high eras of SAE and severe infections.
.
